Cantor Fitzgerald initiated coverage of Replimune (REPL) with an Overweight rating and no price target ahead of RP1’s FDA action date of July 22 in advanced melanoma. The firm sees a “clearer path” for accelerated approval of RP1 citing positive regulatory signs, including breakthrough therapy designation, no panel meeting, and completion of a late-cycle inspection. Physicians perceive RP1 as having a competitive risk/benefit profile relative to available options, says Cantor, which projects $497M in adjusted sales of RP1 by 2030, and $828M by 2040.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune price target raised to $22 from $14 at Piper Sandler
- Replimune presents two posters on data updates for RP1 at 2025 ASCO
- Biotech Alert: Searches spiking for these stocks today
- Replimune Group’s Internal Control Weaknesses Threaten Financial Stability and Investor Confidence
- Replimune files $250M mixed securities shelf
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue